Nektar Therapeutics

Exelixis, Inc.

Symphony Evolution, Inc.

Genentech, Inc.

Other

Nektar Therapeutics (india) Pvt. Ltd.

Neel Kumar Anand

Tsze Tsang

Kenneth D Rice

Csaba J Peto

Joerg Bussenius

Abigail R Kennedy

Charles M Blazey

Simona Costanzo

Larisa Dubenko

Zhongxu Ren

Angie Inyoung Kim

Jean-Claire Limun Manalo

Owen Joseph Bowles

Bo-Liang Deng

Franco J Duarte

Jeffry Kimo Curtis

Steven Charles Defina

Pankaj Sharma

Anagha Abhijit Joshi

Wen Zhang

Jennifer A Riggs-Sauthier

Lin Cheng

Elena S Koltun

Naing N Aay

Haiying Cai

Devendrapratap Singh

Natalia Aurrecoechea

Donogh John Roger O'Mahony

Bhalchandra V Joshi

Saul Kivimae

YongQi Mu

C Gregory Sowell

Nathan Guz

Chris Allen Buhr

Amy Lew Tsuhako

Sunghoon Ma

Sriram Naganathan

Matthew Pfeiffer

Jason Yang

Amit Srivastava

Tracy Bostick

Moon Jung Kim

Antoni Kozlowski

Xiaoming Shen

John M Nuss

Timothy A Riley

Longcheng Wang

Erick Wang Co

Richard George Khoury

Xuyuan Gu

Sergey Epshteyn

Mohamed Ibrahim

Tae-Gon Baik

Arlyn Arcalas

Yuan Song

Xuejun Yuan

Baili Chen

Takahiro Miyazaki

Jonathan Zalevsky

Vijay Kumar Khatri

Michael Lixin Shen

Aleksandrs Odinecs

Wei Xu

Yong Wang

Timothy Patrick Forsyth

James William Leahy

David J Matthews

Lynne Canne Bannen

Vasu Jammalamadaka

Larry Wayne Mann

Morrison B Mac

Jeff Z Chen

Ping Huang

Grace Mann

Tai Phat Huynh

Patrick C Kearney

Peter Lamb

Craig Stacy Takeuchi

Cristiana A Zaharia

Jason Jevious Parks

Lisa Esther Dalrymple

Donna Tra Le

Diva Sze-Ming Chan

Xian Shi

Hongwang Du

Peiwen Zhou

Rhett Ronald Klein

Wai Ki Vicky Chan

Kevin Luke Schnepp

Zerom Tesfai

Katherine Lara

Jason R Harris

Eileen E Jackson-Ugueto

Mary Tagliaferri

Steven Charles DeFina

Jeff Chen

Erik Krogh-Jespersen

Stephanie Ng

Maurizio Franzini

Jeffrey Kimo Curtis

The instant disclosure provides novel adenosine receptor antagonist compounds, compositions, methods of making and methods of using. In a further aspect, a method of treating a subject in need thereof, comprising administering a therapeutically effective amount of any one or more of the compounds described herein. In some embodiments, the subject has cancer and the method is a method of treating cancer.

Adenosine 2 receptor antagonists

Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xis independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods.

Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods

Provided is a method of administering to a patient having cancer: (a) a 4-1BB agonist; (b) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and/or (c) a toll-like receptor agonist, as well as related compositions, kits and compositions.

Immunotherapeutic tumor treatment method

Disclosed herein are methods in the field of cancer immunotherapy that involve the treatment of a subject having cancer by administering to the subject a toll-like receptor 7/8 (TLR7/8) agonist in combination with a long-acting IL-2Rβ-biased agonist and a programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis inhibitor, and related compositions, dosage forms, and kits.

Provided are multi-arm polymer conjugates of Toll-Like Receptor ('TLR') agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: (I) or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and &#x2014;NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2R&#x3b2;-activating amount of a long-acting, IL-2R&#x3b2;-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods.RQ-POLY-Xr-TLR7/8 AG)&#x2003;&#x2003;(I)

Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.

MEK inhibitors and methods of their use

Disclosed herein is a process of making a compound of formula I The compound of formula I is an inhibitor of MEK and thus can be used to treat cancer.

Process for making compounds for use in the treatment of cancer

Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.

N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the &#x3ba; opioid receptor

Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof:  The compounds of Formula I described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.

Kappa opioid agonists and uses thereof

Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.

Opioid agonists and uses thereof

The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.

Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine

The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of the invention, a compound according to Formula I is provided: and pharmaceutically acceptable salts thereof, wherein R-Rare as described herein. 

Morphinan derivatives for the treatment of neuropathic pain

The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.

Oligomer-containing benzamide-based compounds

Provided are compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, R, R, and Rare as described herein. The compounds of Formula I are agonists of the kappa opioid receptor and relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.

Growing community of inventors

San Mateo, CA, United States of America

Neel Kumar Anand